OOIR: Observatory of International Research

Papers

(The TQCC of European Journal of Health Economics is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Education and medication use later in life and the role of intelligence	103
Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication	54
Psychometric properties and general population reference values for PROMIS Global Health in Hungary	38
The hidden cost of sophistication: economic complexity and obesity	34
Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries	31
Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial	30
Should Scotland provide genome-wide sequencing for the diagnosis of rare developmental disorders? A cost-effectiveness analysis	24
Domain-specific discounting of health and money: implications for health technology assessment	23
Risk equalization and prevention	23
Economic value of non-professional care in Spain. An analysis of the last decade	22
Pragmatic randomized controlled trial comparing a complex telemedicine-based intervention with usual care in patients with chronic conditions	22
Patient-level cost analysis of subfertility pathways in the Dutch healthcare system	20
Comparing the measurement properties of the EQ-5D-Y-3L, EQ-5D-Y-5L and CHU9D in children and adolescents: a measurement property study	20
Prescription opioids and economic hardship in France	20
Cost awareness among intensivists in their daily clinical practice: a prospective multicentre study	19
Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan	19
Nothing about us, without us? A reflection on and call for involving children in the process of valuing child health	18
Replay to: Comparison of EQ-5D-5 L and EORTC QLU-C10D utilities in gastric cancer patients	18
Setting incentives right with long-term risk adjustment	18
Expensive today but cheaper tomorrow: lifetime costs of an active middle ear implant compared to alternative treatment options	16
Primary care services and emergency department visits in blended fee-for-service and blended capitation models: evidence from Ontario, Canada	16
From test to rest: evaluating socioeconomic differences along the COVID-19 care pathway in the Netherlands	16
Workload and short sickness absences in a cohort of Finnish hospital employees	16
Economic assessment of abemaciclib for the adjuvant treatment of luminal HER2- breast cancer from the perspective of the Spanish health system	15
Real-world patterns of healthcare use, costs, and survival in diffuse large B-cell lymphoma: a nationwide Swedish register study	15

Multinational stakeholder engagement to inform future development and refinement of the EuroQol toddler and infant populations (EQ-TIPS)	15
Informing decisions in light of parameter uncertainty – an economic evaluation of the adjuvanted recombinant herpes zoster vaccine in Sweden	14
Impact of postoperative in-hospital continuous vital sign monitoring on healthcare costs, resource utilization and labor market outcomes	14
Health-related quality of life in patients with alcohol use disorder: comparing instruments and mapping from clinical measures to preference-based measures	14
Mobile money and households’ ability to respond to health shocks in Africa: Evidence from Madagascar	14
Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma	14
The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands	14
Comparing EQ-5D-5L and SF-6Dv2 utilities with QLU-C10D utilities in hematologic cancer patients	13
Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade	13
The causal effect of catastrophic health expenditure on poverty in Poland	13
Breaking the rules: decision-making under absolute resource constraints	13
On spillovers in economic evaluations: definition, mapping review and research agenda	13
Life-cycle health effects of compulsory schooling	12
Healthcare resource utilization and costs of letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation in a real-world, multi-centre study in Germany	12
Benefits beyond health in the willingness to pay for a quality-adjusted life-year	12
How perceptions of bone marrow donation costs affect donation behavior: survey evidence from a large donor registry	12
Do EQ-5D-Y-3L value sets have common properties, and how do they compare to EQ-5D-5L value sets?	12
Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands	12
Correction: AOTMiT reimbursement recommendations compared to other HTA agencies	12
The cost-effectiveness of value-based insurance design initiatives in managing cardiometabolic diseases: a systematic review	12
A principled approach to non-discrimination in cost-effectiveness	11
The trade-off between health system resiliency and efficiency: evidence from COVID-19 in European regions	11
Healthcare costs of foodborne diseases in the United States: an analysis using electronic health records	11
Psychometric properties comparison of EQ-5D-Y-3L and CHU-9D in children with adenoid hypertrophy	11
Analyzing nurses’ decisions to leave their profession—a duration analysis	11
The social value of gambling: surplus estimates by gambling types for France	11
Availability of pharmacological treatments for multiple myeloma in Spain	11
Do we agree on health state outcomes? A review of measurement agreement between time-trade off and other utility measures	11
The impacts of working from home on individual health and well-being	10
Who pays and Who benefits? A distributional health-economic evaluation of strengthening the UK soft drinks industry levy	10
Adverse selection and consumer inertia: empirical evidence from the Dutch health insurance market	10
Unlocking herpes zoster vaccination value in Finland: return on investment and actuarial model	10
Time value of informal care of people with alzheimer’s disease in Spain: a population-based analysis	10
Costs attributable to hypercholesterolemia in a single period and over the life cycle	10
Economic value of diastasis repair with the use of mesh compared to no intervention in Italy	10
Is next generation sequencing for the diagnosis of rare diseases worth its cost? A user-based approach to valuation	9
Changes in spending, quality indicators, and provider experiences following the introduction of a population-based payment model in dutch primary care: a mixed methods evaluation	9
Valuation of the EQ-5D-3L in Jordan	9
Does chronic disease coverage for outpatient care affect healthcare utilization and expenditures in China? Evidence from an administrative claim dataset	9
Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis	9
Do mobile hospital teams in residential aged care facilities increase health care efficiency: an evaluation of French residential care policy	9
Evaluating hospital performance	9
How tax structures for retail cannabis shape cannabis use among youth and young adults: evidence from a volumetric choice experiment	9
Demographic and health impacts of women’s bodily autonomy: switching prescription requirements for emergency contraceptives	9
Pharmacy cost groups for the German morbidity-based risk compensation scheme	9
Estimating QALYs in adults with cerebral palsy: mapping the San Martin scale to the EQ-5D-5L for economic evaluation	9
Cancer specific health utilities - QLU-C10D country value sets for Belgium, Hungary, Portugal and the Republic of Korea – an international valuation study	8
Scales and size-quality outcomes in adult learning disability residential care: evidence from the UK	8
Forward-looking Behavior in Health Insurance	8
Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2021: an observational study from the French national health data system	8

The Italian National Health Service: still alive for long?	8
Does medial tourism promote growth in healthcare sector?	8
Tenders for generics and biosimilars: a challenging purchasing policy	8
Cost-effectiveness analysis (CEA) of ovarian cancer preventive strategies for women with BRCA1/2 pathogenic variants: the role of surveillance	8
Significant healthcare burden and life cost of spinal muscular atrophy: real-world data	8
Measuring and decomposing income inequalities in child and adolescent mental health in the UK	8
Alcohol prices, the April effect, and the environment, in violence-related injury in England and Wales	8
Modeling European health systems: an ideal chain of services	8
The ACA Medicaid expansions and abortion rates among young adults	8
What hospital quality indicators matter to patients? Results from a general population survey	8
Exploring the consequences of including off-patent prices in reimbursement decisions for patented drugs	7
Cost-utility of cochlear implantation in single-sided deafness and asymmetric hearing loss: results of a randomized controlled trial	7
How are patient inputs considered in HTA? A thematic document analysis of NICE ultra-rare disease appraisals	7
The link between physician motivation and care	7
Getting fairer over time? Assessing changes in health technology funding processes using the accountability for reasonableness (A4R) framework	7
Psychometric benefits of adding four bolt-ons (skin irritation, self-confidence, social relationships and sleep) to EQ-5D-5L compared to PROMIS-29 and Skindex-16 in patients with psoriasis and atopic	7
Cost-effectiveness of two online interventions supporting self-care for eczema for parents/carers and young people	7
Challenges for health systems seeking to embrace virtual health care for population health	7
Economic evaluation on dental caries preventive interventions for Australian children using a priority-setting approach	7
Obtaining preference scores for an abbreviated self-completion version of the Teen-Addiction Severity Index (ASC T-ASI) to value therapy outcomes of systemic family interventions: a discrete choice ex	7
Economics of hypothalamic obesity in patients with craniopharyngioma and other rare sellar/suprasellar tumors	6
Measuring outcomes for loneliness research: examining the appropriateness of the EQ-5D-5 L and EQ-HWB	6
Referring physicians' intention to use hospital report cards for hospital referral purposes in the presence or absence of patient-reported outcomes: a randomized trial	6
Assessing Taiwan’s pay-for-performance program for diabetes care: a cost–benefit net value approach	6
Assessment of health state utilities associated with adult and pediatric acid sphingomyelinase deficiency (ASMD)	6
Costs of productivity loss up to two years after ischaemic stroke	6
Personnel shortages and the provision of long-term care: an empirical analysis of German nursing homes	6
Paid and unpaid productivity losses across 28 European countries due to excess deaths and COVID-19 deaths from 2020 to 2023	6
Disclosing the ‘Big C’: what does cancer survivorship signal to employers?	6
Recovery of suspended reimbursements of high-cost drugs subjected to monitoring registries and negotiated agreements (MEAs): a tool for governance and clinical appropriateness in the Italian reality	6
Public preferences for saving lives versus life-years: evidence from a person-trade-off experiment in 12 countries during the COVID-19 pandemic	6
Trends and drivers of pharmaceutical expenditures from systemic anti-cancer therapy	6
The health and long-term care costs in the last year of life in The Netherlands	6
Self-interest, positional concerns and distributional considerations in healthcare preferences	6
Ex ante evaluation of risk adjustment models for prospective provider payment: a conceptual framework and empirical application	5
Health inequalities and subjective wellbeing	5
Modeling European health systems: a theoretical exercise	5
A critical review of the use of R2 in risk equalization research	5
Generating EQ-5D-3L health utility scores from the Edinburgh Postnatal Depression Scale: a perinatal mapping study	5
Closing the first wave of drug innovativeness in italy: final evidence from 2017 to 2025	5
Estimating cost savings from reducing antibiotic overprescription in european general practices	5
One week versus three to five weeks of plaster cast immobilization for nonreduced distal radius fractures, a cost effectiveness analysis embedded in a stepped wedge cluster randomized controlled trial	5
Does health technology assessment compromise access to pharmaceuticals?	5
Health state utilities associated with X-linked retinitis pigmentosa (XLRP)	5
Unravelling heterogeneity in efficiency measurements: a case study of public hospitals in Spain	5
Comparing EQ-5D-5L, PROPr, SF-6D and TTO utilities in patients with chronic skin diseases	5
A systematic review of economic models comparing in-centre haemodialysis interventions: challenges for demonstrating cost-effectiveness in the context of high background dialysis costs	5
The effect of displaying laboratory test prices on physicians’ ordering behaviour: a systematic review of European studies	5
A cross-country comparison of the psychometric performance of SF-6Dv2 and EQ-5D-5L	5
Long-term costs associated with healthcare use of people with cancer in Scotland	5
Does diagnostic testing always decrease antibiotics prescriptions?	5
Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment	5
Obesity and metabolic state are associated with increased healthcare resource and medication use and costs: a Finnish population-based study	5
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy	5
Time preferences and COVID-19 vaccination uptake	5
The performance of the EQ-HWB-S as a measure of quality-of-life of caregivers in families that have experienced adverse events	5